Texas-based AI biopharmaceutical company Lantern Pharma has launched a new wholly-owned subsidiary called “Starlight Therapeutics,” dedicated to developing novel treatments focused on the central nervous system (CNS) and brain cancers.
Following the launch of Starlight, Lantern’s small molecule candidate, LP-184, will be referred to as STAR-001 for CNS indications while Lantern will continue to evaluate and advance LP-184 for other non-CNS indications.
The formation of Starlight is expected to increase the probability of securing partnerships with other biotech and biopharma companies that focus on CNS cancers. Starlight will also be able to leverage Lantern’s AI-powered platform, RADR, to accelerate the discovery of novel therapeutics.
Lantern expects to initiate Phase Ia clinical trials of STAR-001 for a number of cancer indications, including glioblastoma (GBM), brain metastases, and several rare pediatric CNS cancers from mid-2023. Following this, Starlight will be solely responsible for conducting further clinical trials for STAR-001.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.